Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 598 + liraglutide
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
AMG 598 + liraglutide is a combination therapy under early-stage clinical investigation for obesity. AMG 598 is a human monoclonal antibody with immunomodulatory properties, developed by Amgen, while liraglutide is a glucagon-like peptide 1 receptor agonist, already approved for weight management. This combination is being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics, with the aim to potentiate weight loss by leveraging both immunomodulation and incretin-based therapy[1][2][7].
- Other names
- AMG-598AMG598AMG 598
02
Targets
Beyond the preview
Go deeper on AMG 598 + liraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 598 + liraglutide.